IDirect HealthCheck Sep16

Monthly Update
September 21, 2016
Health Check
Sector View
Positive
Index Performance as on September 21, 2016
Return (%)
Return (%)
1M
3M
YTD
1Y
CNX 500
1.3
8.8
11.4
12.7
Nifty
1.3
6.8
10.5
10.0
NSE Pharma
1.2
10.4
-1.9
-7.7
Stocks Performance
Mcap
Return (%)
Company
1M
3M
YTD
1Y 21-Sep
Sun Pharma.Inds.
-0.6
Lupin
-1.9
5.8
-5.0
-13.5 187445
6.6
-15.9
Dr Reddy's Labs
-17.8
69689
4.7
3.4
1.4
-20.3
52244
Cipla
8.0
24.4
-7.4
-7.4
48323
Aurobindo Pharma
5.6
12.0
-7.8
13.5
47261
Cadila Health.
4.9
24.1
19.5
-1.6
40069
Divi's Lab.
2.3
19.0
15.1
19.0
35287
Torrent Pharma.
4.2
21.6
12.7
13.8
27360
Glenmark Pharma.
4.0
18.1
-2.4
-12.0
25394
Glaxosmit Pharma
-10.0
-20.0
-15.2
-16.1
23806
Biocon
11.6
30.5
82.5
114.9
18911
Apollo Hospitals
-5.8
0.4
-10.5
-3.8
18251
Ajanta Pharma
-0.2
34.1
47.6
35.8
17298
Alembic Pharma
1.1
20.3
-6.2
-5.8
12310
Natco Pharma
-0.8
26.9
10.0
41.2
11094
Jubilant Life
24.1
84.3
52.7
81.3
10007
Wockhardt
11.8
-1.0
-41.7
-35.4
9851
Syngene Int.
13.8
17.9
15.7
49.7
9641
Strides Arcolab
4.6
-5.2
-20.0
-14.1
Pfizer
4.7
5.9
-15.3
-22.4
-22.2
Ipca Labs.
15.2
20.2
-20.3
Indoco Remedies
8.1
25.7
1.2
1.1
Unichem Labs.
-2.7
1.1
-1.6
-3.6
Market cap in | crore
Price movement
15000
14000
13000
12000
11000
10000
9000
8000
7000
6000
5000
Sep-15
6000
4000
CNX Pharma
On an innovation front, Glenmark has announced the discovery and

initiation of investigating new drug (IND) enabling studies for a novel clinical
development candidate, GBR 1372. GBR 1372 adds to Glenmarks
expanding oncology portfolio of biologics including GBR 1302 (HER2xCD3
bispecific antibody) and GBR 1342 (CD38xCD3 bispecific antibody) based on
its proprietary BEAT technology. Glenmark is likely to file an IND with the
USFDA in 2HFY18. Glenmark presently has a pipeline of six Novel Biologics
Entity (NBE) and tow Novel chemical Entity (NCE) in various stages of
preclinical and clinical development.
Glenmark has entered into a tie-up with US based Particle Sciences, Inc. to
develop and market a generic version of Celgenes oncology injection
7457
Abraxane (paclitaxel protein (albumin)-bound particles for injectable
3051
2389 M suspension). As per the agreement, Glenmark has obtained global exclusive
marketing and distribution rights of the product upon commercialization.
Particle Sciences will develop this product exclusively for Glenmark.
8000
Jun-16
The Indian pharmaceutical market (IPM) grew 15% YoY to | 9643 crore for
the month of August, the highest growth in nine months mainly due to
recovery in volume growth (albeit on lower base) and seasonality benefit.
The growth was largely driven by volumes increase 9.1% followed by
price hikes- 2.9% and new product launches- 2.9%. On a MAT basis, IPM
growth stood at 10.5% YoY to | 102537 crore.
9211
10000
Mar-16
In a significant tie-up, Syngene has opened a dedicated centre for US

based leading biologics dedicated player Amgen Inc. in Bangalore. This
centre, christened as Syngene Amgen Research and Development Centre
(SARC), will be Syngenes fourth such exclusive R&D centre and the first for
a biologics company. Syngene already operates dedicated R&D centres for
Bristol-Myers Squibb (BMS), Abbott Nutrition (Abbott) and Baxter Inc. SARC
will be staffed by a team of more than 100 Syngene scientists, working with
Amgen researchers around the world on the discovery and development of
innovative medicines.
9140
12000
Dec-15
Syngene opens new centre; Domestic growth

recovers
Sep-16
Nifty (RHS)
Research Analyst
Siddhant Khandekar
siddhant.khandekar@icicisecurities.com
Mitesh Shah
mitesh.sha@icicisecurities.com
ICICI Securities Ltd. | Retail Equity Research
On a regulation front, Indocos Goa plant II (sterile and solid dosages facility)
received six 483 observations from USFDA. Inspection was conducted
between 31st August 31, 2016 to 4th September, 2016. The injectable ANDA
filings triggered this inspection. In Mar 2016, Goa plant received
establishment inspection report (EIR) for inspection conducted in July 2015.
No red flag on earnings front; regulatory worries waning
Despite pricing pressure and client consolidation in the US, which were
thought to be the significant headwinds post Q4FY16 numbers, most of the
players (barring few) managed to expand volumes in Q1 thereby
neutralising these headwinds. Regarding USFDA issues the Indian players
have moved on and seem better prepared than 12-18 months ago as
reflected by growing number of EIRs by the USFDA for Indian facilities. The
Indian formulations also did reasonably well despite NLEM / FDC issues. We
expect earnings momentum to continue on the back of incremental product
launches in the US and likely positive outcome from the USFDA reinspections besides normalising of Indian formulations growth. We expect
healthcare universe revenue, EBITDA and PAT to grow at a CAGR of 12%,
13% and 16%, respectively, in FY16-18E. The growth will be steered by US
(~13% CAGR over FY16-18E) and Indian formulations (~14% CAGR over
FY16-18E).
Regulatory approvals
Exhibit 1: Summary of USFDA approvals for Aug, 2016
[5
Company
Sun Pharma
Natco Pharma
Aurobindo Pharma
Sun Pharm
Aurobindo Pharma
Glenmark Pharma
Aurobindo Pharma
Dr Reddys Labs
Jubilant
Aurobindo Pharma
Jubilant
Cipla
Sun Pharm
Dr Reddys Labs
Ajanta Pharma
Drug Name
Metformin Hydrochloride
Oseltamivir Phosphate
Linezolid
Buprenorphine Hydrochloride; Naloxone Hydrochloride
Galantamine Hydrobromide
Triamcinolone Acetonide
Esomeprazole Sodium
Paricalcitol
Felodipine Er Tablets
Omeprazole; Sodium Bicarbonate
Telmisartan Tablets
Trospium Chloride
Morphine Sulfate
Nitroglycerin
Olanzapine
Company
Torrent Pharms
Lupin
Ajanta Pharma
Drug Name
Rosuvastatin Calcium
Paroxetine
Eletriptan Hydrobromide
Final Approvals
Therapeutic Area
Anti-Diabetic
Anti-Infective
Anti-Bacterial
Anti-Addictive
Anti-Alzheimer
Dermatology
GI
Hormonal
CVS
Gi
CVS
Cns
Pain Management
CVS
Cns
Tentative Approvals
Therapeutic Area
CVS
Anti-Depressant
Pain Management
Innovator company
Generic Version of
Santarus Inc
Glumetza
Roche
Tamiflu
Harmacia
Zyvox
Indivior Inc
Suboxone
Janssen Pharma
Razadyne
NA
NA
Astrazeneca
Nexium IV
Abbvie
Zemplar
Astrazeneca
Plendil
Santarus
Zegerid
Boehringer Ingelheim Pha Micardis
Valeant
Wellbutrin XL
Purdue Pharma
Ms Contin
Pfizer
Nitrostat
Lilly
Zyprexa
Market Size
US$ 1200 million
US$ 403 million
US$ 87 million
NA
NA
US$ 4.4 million
NA
US$ 110 million
NA
NA
US$ 250 million
US$ 792 million
NA
US$ 108 million
NA
Innovator company
Astrazeneca
Apotex
Pfizer
Market Size
NA
NA
NA
Generic Version of
Crestor
Paxil
Relpax
CNS: Central Nervous System; CVS: Cardiovascular,GI: Gastro Intestinal, NA: Not available;
Source: USFDA, ICICIdirect.com Research
M&As, Demergers, Tie-ups and JVs
DRL to market three of Amgens Biological drugs in India

DRL will be commercialising Amgens three biological drugs XGEVA
(denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India in
the therapeutic areas of oncology and osteoporosis.
Cadila partners Takeda for chikungunya vaccine
Cadila health entered in to a strategic partnership with Japan's Takeda
Pharma to develop vaccine for vector borne chikungunya. The agreement
includes early stage development to the final commercialisation of the
vaccine. As per management, there is currently no vaccine to prevent
chikungunya virus infection.
Glenmark Signs agreement with Particle Sciences For gAbraxane
Glenmark Pharma entered into a strategic agreement with Particle Sciences,
Inc. to develop and market a generic version of Celgenes oncology
injection Abraxane (paclitaxel protein (albumin)-bound particles for
injectable suspension). As per the agreement, Glenmark has obtained global
exclusive marketing and distribution rights of the product upon
commercialization. Particle Sciences will develop this product exclusively
for Glenmark, and shall receive certain milestone payments during various
stages of the products development from Glenmark, including royalties on
sales. Development of the product has been initiated for the US market and
Glenmark intends to file the ANDA in FY19. The product will be
subsequently filed in other key markets across the globe. Branded Abraxane
marketed globally by Celgene has reported sales of US$ 967 million in
CY15.
Indoco acquires manufacturing plant at Baddi
Indoco Remedies has acquired the manufacturing facility at Baddi from
Micro Labs Ltd. The facility is spread over an area of 18000 sq mt, out of
which 11,000 sq mt is the built-up area. It produces 4.3 billion tablets and 50
Page 2
million capsules p.a. With this acquisition, Indoco will now have six
facilities for formulations and three for APIs.

Price cuts / New Launches / Recalls/Approvals
Glenmark announces Initiation of IND studies for GBR 1372

Glenmark has announced the discovery and initiation of investigating new
drug (IND) enabling studies for a novel clinical development candidate, GBR
1372. GBR 1372 is the third Bispecific Antibody and also Glenmarks third
clinical candidate targeting an oncology indication.
Law suits / Court rulings / Settlements / Regulatory Issues
Indoco Goa Plant II received six observations from USFDA

Indoco remediess Goa plant II (sterile and solid dosages facility) received
six 483 observations from USFDA. Inspection was conducted between 31st
August 31, 2016 to 4th September, 2016. The injectable ANDA filings
triggered this inspection. As per the management, none of these
observations are related to data integrity issue. It expects to complete the
corrective and preventive actions within a period of 30 days. In Mar 2016,
Goa plant received establishment inspection report (EIR) from USFDA for
inspection conducted in July 2015.
Taro Pharma under anti-trust scanner for price hike
Taro Pharma has been summoned by the US Department of Justice (DOJ)
over its pricing policy. The DOJ's investigation comes at a time when
pharma companies in the US are being accused of exorbitantly increasing
the price of essential medicines.
US FDA completes Aurobindo's Unit IV audit
The company's management has indicated that the USFDA has completed
inspection of unit IV plant at Andhra Pradesh and issued 2-3 observations.
As per the management, the observations are minor which should not
impact the approval of pending products from the site.
Aurobindo, Sun and Lupin recall drugs in the US
Lupin Pharma is recalling 26436 bottles of Lisinopril Tablet from US due to
deviation from current good manufacturing practice (CGMP). Sun Pharma is
also recalling 12109 HDPE bottles of Carvediol Tablets due to Failed
Impurities/Degradation Specifications. As per the report, all the recalls are
fall under a class III recall category. Aurobindo is also recalling 23016 bottles
of Pantoprazole Sodium Delayed-Release Tablets under Class II category
due to received a market complaint stating the presence of one foreign
tablet (Montelukast Sodium Chewable Tab 4mg) in the product bottle of
Pantoprazole.
Others
Syngene sets up R&D centre for Amgen in Bengaluru

Syngene has announced the establishment of a dedicated centre for
Amgen, Inc. in Bangalore. This centre, called Syngene Amgen Research and
Development Centre (SARC), will be Syngenes fourth such exclusive R&D
centre and the first for a biologics company. Syngene already operates
dedicated R&D centres for Bristol-Myers Squibb (BMS), Abbott Nutrition
(Abbott) and Baxter Inc. SARC will be staffed by a team of more than 100
Syngene scientists, working with Amgen researchers around the world on
the discovery and development of innovative medicines.
Q1FY17 Results
Apollo Hospital- Lower occupancy, Ind AS hit margins

Standalone revenues increased 12% YoY to | 1465 crore on the back of a
22% increase in pharmacy business to | 633 crore. Healthcare business
grew 6% to | 833 crore. EBITDA margins declined 85 bps to 12.8% on the
back of adverse product mix and Ind AS, which impacted EBITDA margins
of healthcare services negatively by 130-140 bps. Adjusted net profit degrew 18% to | 72 crore due to higher interest cost and lower EBITDA.
Page 3
Exhibit 2: Patent litigations (12 months)

[5
Month
Sep-15
Sep-15
Sep-15
Sep-15
Oct-15
Oct-15
Oct-15
Oct-15
Oct-15
Oct-15
Oct-15
Nov-15
Nov-15
Nov-15
Nov-15
Nov-15
Nov-15
Nov-15
Nov-15
Nov-15
Nov-15
Nov-15
Nov-15
Nov-15
Nov-15
Dec-15
Dec-15
Dec-15
Dec-15
Dec-15
Dec-15
Jan-16
Jan-16
Feb-16
Feb-16
Feb-16
Mar-16
Mar-16
Apr-16
May-16
Jun-16
Jun-16
Jun-16
Jun-16
Jun-16
Jul-16
Jul-16
Jul-16
Jul-16
Jul-16
Aug-16
Aug-16
Aug-16
Aug-16
Aug-16
Aug-16
Aug-16
Aug-16
Aug-16
Aug-16
Innovator
ANDA Filer
Brand Name
Jazz Pharma
Gilead Sciences Inc.
Horizon Pharma
Bayer Pharma
Merck
Salix Pharmaceuticals, Inc.
Takeda Pharma
Janssen Pharma
Novartis Pharma
Otsuka Pharma
AstraZeneca
AstraZeneca
Novartis Pharma
Allergan
Shire Pharma
Dexcel Pharma
Dexcel Pharma
Cephalon Inc.
Cosmo Techs
Pfizer
Vanda Pharma
Forest Labs
Jazz Pharma
Otsuka Pharma
Symed Labs
UCB Inc.
Unimed Pharma
Helsinn Healthcare
Sanofi-Aventis
Otsuka Pharma
Merz Pharma
Dow Pharma
Cubist Pharma
Bayer Pharma
Bristol Myers Squibb
Janssen Products LP
Shire Canada
Daiichi Sankyo
Daiichi Sankyo
Daiichi Sankyo
Apicore
UCB, Inc.
Gilead
Janssen Biotech
Sanofi-Aventis
Sanofi-Aventis
Roche
AstraZeneca AB
Hyperion Therapeutics
Gilead Sciences, Inc.
Lupin
Gilead Sciences Inc
Shire LLC
AbbVie Inc.
Galderma Laboratories, LP
Reckitt Benckiser Inc.
Takeda Pharma
Dexcel
Shionogi Inc
Nestle Skin Health
Lupin
Lupin
Lupin
Alembic Pharma
Lupin
Taro Pharma
Aurobindo
Aurobindo
Natco Pharma
Zydus Pharma
Alembic Pharma
InvaGen Pharma
Dr. Reddy's Labs
Aurobindo Pharma
Lupin
Sun Pharma
Dr. Reddy's Labs
Aurobindo Pharma
Lupin
Dr. Reddy's Labs
Lupin
InvaGen Pharma
Sun Pharma
Alkem Labs
Glenmark Pharma
InvaGen Pharma
Dr. Reddy's Labs
Dr. Reddy's Labs
Glenmark Pharma
Ajanta Pharma
Taro Pharma
Taro Pharma
Dr. Reddy's Labs
InvaGen Pharma
Cipla
Lupin
Lupin
Torrent Pharma
Alembic Pharma
Aurobindo Pharma
Aurobindo Pharma
Aurobindo Pharma
Aurobindo Pharma
Glenmark Pharma
Cadila Healthcare
Cadila Healthcare
Cadila
Aurobindo
Lupin
Aurobindo
InvaGen Pharma
Hetero
Alkem Lab
Amgen Inc.
SEEGPharm
Sun Pharma
Dexcel Pharma
Aurobindo
Hi-Tech Pharmacal
Perrigo Co.
Xyrem
Tamiflu
Pennsaid
Staxyn
Beyaz
Moviprep
Prevacid
Xarelto
Gleevec
Abilify
Brilinta
Brilinta
Exelon Patch
Acular LS
Lialda
Omeprazole
Omeprazole
Nuvigili
Uceris
Toviaz
Fanapt
Viibryd
Xyrem
Abilify
Zyvox
Zyrtec-D
Androgel
Aloxi
Multaq
Abilify
Naftin
Onexton
Cubicin
Xarelto
Reyataz
Prezista
Daliresp
Benicar
Benicar
Benicar
LYMPHAZURIN
VIMPAT
EMTRIVA
ZYTIGA
MOZOBIL
MOZOBIL
Aloxi
Nexium 24HR
RAVICTI
Truvada
Antara
Complera
Fosrenol
Humira
Metrogel
Mucinex
Prevacid
Prilosec
Ulesfia
MIRVASO
API
Used for
Sodium Oxybate
Narcolepsy
Oseltamivir
Influenza
Diclofenac
Osteoarthritis
Vardenafil Hydrochloride
Sex Stimulant
Drospirenone
Birth control
Polyethylene glycol electrolyte soln
Gastro Intestinal
lansoprazole
Stomach ulcers
Rivaroxaban
Blood Thinner
Matinib Mesylate
Anti-cancer
Aripiprazole
Schizophrenia
Ticagrelor
CVS
Ticagrelor
CVS
Rivastigmine
Dementia
Ketorolactromethamine
Ocular Pain
Mesalamine
Ulcerative Colitis
Omeprazole
GI
Omeprazole
GI
Modafinil
CNS
Budesonide
GI
Fesoterodine
Urotherapy
Iloperidone
Schizophrenia
Vilazodone
Anti-depressant
Gamma-hydroxybutyric acid
CNS
Aripiprazole
Schizophrenia
Linezolid
Anti-Infective
Cetirizine
Respiratory
Testosterone
Low Testosterone
Palanosetron
Nausea
Dronedarone
Atrial Fibrillation
Aripiprazole
Schizophrenia
Naftifine Hydrochloride
Fungal Infection
Cindamycin Phosphate and Benzoyl Peroxide Acne
Daptomycin
Antibiotic
Rivaroxaban
Blood Thinner
Atazanavir
HIV
Darunavir
HIV
Roflumilast
Respiratory
Olmesartan
Anti-depressant
Olmesartan
Anti-depressant
Olmesartan
Anti-depressant
isosulfan blue
lymphatic imaging agent
lacosamide
partial-onset seizures
emtricitabine
HIV
abiraterone
Oncology
plerixafor
non-Hodgkin's lymphoma
plerixafor
non-Hodgkin's lymphoma
palonosetron hydrochloride
prevention of acute nausea
esomeprazole magnesium
treatment of acid reflux
Glycerol Phenylbutyrate
urea cycle disorders
emtricitabine / tenofovir disoproxil fumarate HIV
fenofibrate
hypercholesterolemia; dyslipidem
Emtricitabine; Rilpivirine Hydrochloride; TenofoHIV
lanthanum carbonate
end stage renal disease
adalimumab
immunosuppressant
metronidazole
rosacea
guaifenesin / pseudoephedrine hydrochloride bronchial congestion
lansoprazole
stomach ulcers
Omeprazole
Heartburn
benzyl alcohol
anti-parasite
brimonidine
Dermatology
Source: Bloomberg, ICICIdirect.com Research
Page 4
The Indian pharmaceutical market (IPM) grew 15.3% YoY to | 9643

crore for the month of August. The growth was driven by volumes
increase 9.1%, price hikes- 2.9% and new product launches- 2.9%
and.
The (Fixed dosage combination) FDCs related market de-grew 11.5%.
Drugs under NLEM list increased 4.5% to |1101 crore while non-NLEM
drugs posted a robust growth of 17.3% to | 8141 crore. Volume growth
in NLEM and Non-NLEM was 14.9% and 9.6% respectively.
Among companies under I-Direct coverage, Indoco, IPCA and Unichem,
glenmark, Alembic and Sun have registered robust growth of 33.7%,
28.0%, 26.4%, 20.9%, 20.5% and 20.3% respectively. DRL, Torrent,
Ajanta, Lupin, Cipla and Cadila registered growth of 17.3%, 12.7%,
10.0%, 9.3%, 8.6% and 6.7% respectively.
Therapy wise, 6 therapies have outpaced the IPM growth. Notable
among them with growth rates- Anti-Malarials 38.6%, Anti infective
19.6%, Respiratory32.3%, Anti Diabetic 19.0%, Pain/Analgesics
15.4% and GI 14.2%.
In all, 340 new brands were launched in Aug-16.
On a MAT basis, IPM growth stood at 10.5% YoY to | 102537 crore.
Domestic companies have grown 17.1%, while MNC companies have
grown 9.0% in Aug-2016.
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
23.0 Oct-15
15.8
14.9
6.7
4.7
20
8.8
12.6
10.1
13.1
9.8
10
5
0
-5
Indian Pharma Market
Source: AIOCD data base, ICICIdirect.com Research
34.0
35
Source: AIOCD data base ; As per AIOCD MAT Aug 2016
30
(%)
Unichem
Torrent
Sun Pharma
Pfizer
Novartis
Lupin
Ipca Labs
19.7
20
10
34.5
28.0
25
15
Indoco
GSK Pharma
Glenmark
DRL
Cipla
40
Cadila
Exhibit 4: Companies growth in domestic market in Aug, 2016

Biocon
SubChronic,
18529.19,
20.3%
10.6
15
13.7
20
Alembic
Acute,
44636.31,
48.8%
Sep-15
25
Industry acute to chronic therapy ratio percentage

Chronic,
28318.03,
31.0%
Aug-15
Exhibit 3: Domestic formulations - growth trend

Jul-15
Brand
Company Therapy
Aug' 16 Aug' 15 Gr. (%)
Corex
Pfizer
Respiratory
315.6
261.7
20.6
308.8
234.4
31.8
Spasmo Prox Wockhardt GI
Lantus
Sanofi
Anti Diabetic
304.5
241.2
26.2
Galvus Met Novartis
Anti Diabetic
295.8
216.4
36.7
Anti-Infectives 295.4
329.2 -10.3
Augmentin GSK
Clavam
Alkem
Anti-Infectives 255.9
221.7
15.4
Volini
Ranbaxy
Pain
236.8
204.3
15.9
Becosules Sun Pharma Vitamins
219.5
257.8 -14.9
Pan
Alkem
GI
205.8
182.3
12.9
Voveran
Novartis
Pain
205.1
161.0
27.3
Source: AIOCD data base
12.2
Top brands in Indian pharma market
IPM grew 15% in Aug- highest growth in 9 months
Ajanta
Therapy
Aug' 16 Aug' 15 YoY (%) July' 16 MoM (%)
Anti-Infectives
1562
1306
19.6
1409
10.9
GI
1138
997
14.2
1133
0.4
Cardiac
1119
1002
11.6
1084
3.2
Vitamins
848
761
11.4
824
2.9
Anti Diabetic
800
672
19.0
755
5.9
Respiratory
771
583
32.3
685
12.6
Pain
694
602
15.4
650
6.9
Derma
554
494
12.2
527
5.3
Neuro
552
504
9.5
527
4.7
Gynaecological
472
426
10.8
473
-0.2
Vaccines
163
163
0.1
172
-5.1
Ophthal
162
156
4.5
155
5.1
Hormones
159
139
14.0
149
6.7
Anti-Neoplastics
149
146
2.1
145
2.7
Others
117
87
35.2
108
8.4
Blood Related
111
102
8.4
107
3.2
Urology
105
91
15.0
101
3.4
Anti Malarials
77
56
38.6
60
28.1
Sex Stimulants
48
42
14.4
48
-0.3
Stomatologicals
43
38
13.4
43
-0.4
(%)
Therapy wise performance (| crore)
12.3
11.9
8.8
19.9
15.6
8.2
12.4
13.5
7.2
2.9
5.8
7.3
Page 5
Sun Pharmaceuticals
Acute : Chronic contribution (MAT Aug16)
Stock Performance
Chronic,
3570.21,
44.5%
150
130
110
90
70
50
SubChronic,
1072.35,
13.4%
Acute,
3376.53,
42.1%
Sep-15
Nov-15
Jan-16
Mar-16
May-16
CNX Pharma
Sep-16
Sun Pharma
Source: NSE, ICICIdirect.com Research
11 to 20
21 to 30
31 to 50
Aug-16
15.8
12.4
14.9
9.9
6.7
3.3
Others
Jul-16
Jun-16
May-16
4.7
4.5
5.2
8.8
7.0
12.3
8.2
9.9
12.6
10.1
13.1
20.3
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
9.8
10
10%
10.6
12.5
7%
11.6
(%)
56%
13.7
15
9%
18.1
20
18%
5.2
25
23.0Oct-15
Sep-15
Aug-15
Exhibit 5: Company growth vis--vis Indian pharma market growth
Brands contribution to domestic sales (MAT Aug16)
Top 10
Jul-16
Sun Pharmaceutical Industries
Exhibit 6: Market share in Indian formulations market
Exhibit 7: Top 10 brands performance

Therapy
Volini
Pain
22.1
19.2
15.2
21.3
3.7
Gemer
Anti Diabetic
17.4
12.3
41.5
16.3
7.0
Rosuvas
Cardiac
17.0
13.0
30.3
16.1
5.1
7.8
Istamet
Anti Diabetic
16.6
12.1
37.4
16.2
2.6
7.2
Levipil
Neuro
14.3
11.7
22.7
14.3
0.4
6.6
Revital H
Vitamins
14.3
10.2
40.2
13.7
4.8
Pantocid
Gastro Intestinal
13.5
11.2
21.0
13.1
3.2
Susten
Gynaecological
12.8
11.5
10.8
12.8
-0.2
Pantocid Dsr
Gastro Intestinal
11.1
9.6
15.5
10.8
3.0
Mox
Anti-Infectives
10.1
8.2
23.3
9.9
1.1
9.6
9.0
8.4
(%)
(| crore)
Brand
8.3 8.3 8.3
8.9 8.9 9.0 8.8 8.9 8.9 8.8

8.7
8.6 8.7
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
Aug-15
6.0
Sun Pharmaceutical Industries
Aug' 16 Aug' 15 Var. (%) July' 16 Var. (%)
Source: AIOCD data base, ICICIdirect.com Research * Included Ranbaxys sales
Exhibit 8: Contribution of therapies to domestic sales (MAT Aug16)
Exhibit 9: Therapy wise performance
Derma
7%
Cardiac
29%
Anti-Infectives
18%
Aug' 16
Aug' 15
YoY (%)
July' 16
MoM (%)
Cardiac
153.6
120.4
27.6
146.0
5.2
Neuro
141.4
117.4
20.5
136.0
3.9
Gastro Intestinal
102.2
87.9
16.2
100.0
2.2
96.5
86.8
11.2
90.8
6.2
Anti-Infectives
Gastro
Intestinal
19%
Neuro
27%
(| crore)
Therapy
Derma
41.0
32.7
25.4
73.1
-43.9
Anti Diabetic
76.3
61.6
23.9
57.3
33.0
Vitamins
35.4
28.6
23.7
38.2
-7.4
Pain
59.6
51.9
14.8
34.3
73.8
Respiratory
33.8
22.7
49.0
30.0
12.7
Gynaecological
29.9
28.2
6.0
30.3
-1.5
Page 6
Cipla
September 21, 2016
Stock Performance
Chronic,
1877.72,
Acute, 41.2%
2119.70,
46.5%
140
120
100
80
60
SubChronic,
556.57,
12.2%
Sep-15
Nov-15
Jan-16
Mar-16
May-16
CNX Pharma
Jul-16
Sep-16
Cipla
11 to 20
21 to 30
31 to 50
Aug-16
14.9
15.8
Jul-16
Jun-16
May-16
12.3
14.2
6.7
8.8
8.8
2.0
Others
6.1
4.7
7.0
3.5
0
Top 10
Apr-16
Mar-16
Feb-16
12.6
4.6
11.5
10.1
Jan-16
Dec-15
Nov-15
21.0
10.0
11% 8%
10
11.0
(%)
13%
10.6
15
43%
13.7
20
25%
13.1
16.6
25
9.8
15.9
23.0Oct-15
Aug-15
Sep-15
Cipla
(| crore)
5.4
Brand
Therapy
5.2
Foracort
Respiratory
16.5
15.3
7.8
16.3
1.6
Duolin
Respiratory
12.4
9.4
31.5
10.8
15.0
Budecort
Respiratory
12.0
11.0
9.1
12.3
-2.5
Seroflo
Respiratory
11.4
10.7
6.7
10.9
5.1
Asthalin
Respiratory
11.4
10.6
7.8
10.3
10.3
Montair Lc
Respiratory
8.0
5.9
35.5
7.3
10.6
Aerocort
Respiratory
8.0
7.8
2.0
7.7
3.8
5.1
5.0
4.8
5.1
5.2
4.9 4.9
4.8
(%)
5.2
5.2
4.9
4.7 4.7
4.6
4.6
4.4
4.5
4.2
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
Aug-15
4.0
Cipla
Azee
Anti-Infectives
7.6
7.7
-0.4
7.9
-3.5
Advent
Anti-Infectives
7.3
5.5
32.6
5.4
35.0
Ibugesic Plus
Pain
7.0
5.4
30.3
6.4
9.7
Other
18%
Respiratory
30%
Urology
5%
Gastro
Intestinal
8%
Cardiac
12%
Anti-Infectives
27%
Therapy
Respiratory
Anti-Infectives
(| crore)
Aug' 16
132.2
Aug' 15
112.8
YoY (%)
1 7.2
July' 16
122.1
MoM (% )
8.3
113.4
109.6
3.5
110.9
2.3
Cardiac
51.1
46.9
8.9
52.0
- 1.7
Gastro Intestinal
37.5
32.3
1 6.0
38.2
- 1.8
Urology
Neuro
20.1
13.6
19.7
15.7
1.8
-1 3.6
20.1
13.2
- 0.1
3.1
Ophthal
13.4
13.8
- 2.8
13.8
- 2.8
Pain
15.8
13.6
1 6.0
14.8
6.9
Derma
V itamins
12.0
7.9
10.9
7.4
9.4
6.5
11.1
8.4
8.0
- 5.5
Dr. Reddys Labs
Stock Performance) Stock Performance

Chronic,
648.79,
30.8%
SubChronic,
405.29,
19.2%
Acute,
1053.63,
50.0%
140
120
100
80
60
Sep-15
Nov-15
Jan-16
Mar-16
May-16
CNX Pharma
Jul-16
Sep-16
Dr. Reddys
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
15.6
14.9
4.3
1.5
6.7
8.8
-1.4
4.1
4.7
7.0
6.7
15.8
31.7
12.6
26.5
10.1
9.8
7.5
13.1
27.4
23.6
23.0
30.7
10.6
14.6
(%)
10
16%
9%
13.7
20
29%
12%
Nov-15
40
30
34%
Oct-15
Aug-15
Sep-15

-10
Top 10
11 to 20
21 to 30
31 to 50
Dr. Reddys Laboratories
Others
2.8
2.7
2.7
(%)
2.6
2.6
2.5
2.5
2.4
2.3
2.3
2.2
2.2
2.6
2.3
2.3
2.3
2.2
2.3 2.2 2.2
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
Aug-15
2.1
Dr. Reddys Laboratories
Gastro
Intestinal
21%
Cardiac
14%
Anti-Infectives
8%
Respiratory
9%
Therapy
Omez D
Gastro Intestinal
9.1
7.2
26.1
8.6
5.7
Omez
Gastro Intestinal
8.9
10.7
-16.7
9.4
-5.5
Peggrafeel
Anti-Neoplastics
7.2
1.7
309.9
5.4
33.2
Grafeel
Anti-Neoplastics
6.3
5.7
12.0
7.9
-20.1
Nise
Pain
5.8
5.4
7.2
5.2
10.5
Atarax
Respiratory
5.6
3.3
70.1
5.1
9.6
Econorm
Gastro Intestinal
5.5
5.7
-4.2
6.5
-16.7
Docetere
Anti-Neoplastics
5.3
2.5
112.9
4.1
28.5
Razo D
Gastro Intestinal
5.2
4.4
19.3
4.7
11.3
Razo
Gastro Intestinal
5.1
3.7
37.7
4.8
6.1

Other
37%
(| crore)
Brand
AntiNeoplastics
11%

Therapy
(| crore)
Aug' 16
Aug' 15
YoY (%)
July' 16
Gastro Intestinal
44.5
41.2
8.0
44.3
MoM (%)
0.5
Cardiac
27.7
27.1
2.0
25.6
8.1
Anti-Neoplastics
35.6
26.0
36.9
28.8
23.7
Respiratory
21.5
15.3
40.8
18.7
14.6
Anti-Infectives
21.1
15.1
39.8
16.3
29.4
Pain
14.5
13.3
9.4
13.4
8.6
Derma
11.4
10.1
12.1
10.7
6.6
Anti Diabetic
5.9
13.5
12.3
9.5
12.7
Urology
8.7
7.2
20.0
8.3
4.1
Neuro
7.3
6.7
7.8
6.6
10.7
Page 8
Lupin
Stock Performance
Acute,
933.57,
31.3%
Chronic,
1428.21,
47.9%
SubChronic,
617.73,
20.7%
140
120
100
80
60
Sep-15
Nov-15
Jan-16
Mar-16
May-16
CNX Pharma
Jul-16
Sep-16
Lupin
13%
11 to 20
Aug-16
13.5
15.8
14.9
11.1
6.7
4.7
-4
21 to 30
31 to 50
Others
3.5
3.4 3.4
Lupin
3.4 3.4 3.3 3.3
Brand
Therapy
(| crore)
Gluconorm-G
Anti Diabetic
15.0
11.4
30.8
14.6
2.2
Budamate
Respiratory
8.4
6.1
39.0
7.6
11.4
Tonact
Cardiac
7.7
8.4
-8.1
7.5
3.6
Rablet-D
Gastro Intestinal
5.2
4.7
12.1
5.4
-3.5
2.7
Rablet
Gastro Intestinal
4.5
4.5
1.1
4.5
1.4
2.5
Tazar
Anti-Infectives
4.2
3.5
20.2
3.8
10.0
2.3
Esiflo
Respiratory
4.0
4.4
-7.5
3.6
11.4
3.3 3.3 3.3 3.3
3.3
3.1
3.2 3.2 3.2
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
2.9
Aug-15
(%)
Jul-16
May-16
8.8
11.7
7.0
9%
Top 10
Jun-16
Apr-16
Mar-16
20.5
Feb-16
12.6
18.4
10.1
12.9
14.5
13.1
Jan-16
Dec-15
Nov-15
21.8
4.7
9.9
11%
9.8
12
7.2
(%)
20%
12.1
47%
10.6
20
13.7
20.9
28
23.0 Oct-15
Aug-15
Sep-15

Lupin
Telekast-L
Respiratory
4.0
3.4
18.9
4.2
-4.4
Cetil
Anti-Infectives
3.9
3.4
14.2
4.2
-6.4
Ramistar
Cardiac
3.7
4.3
-15.2
3.5
3.7
Other
22%
Cardiac
24%
Gastro
Intestinal
8%
Anti Diabetic
12%
Anti-Infectives
21%
Respiratory
13%
(| crore)
Therapy
Aug' 16
Aug' 15
YoY (%)
July' 16
MoM (%)
Cardiac
71.9
70.0
2.8
68.5
5.0
Anti-Infectives
63.9
62.1
2.9
60.8
5.0
Respiratory
38.0
30.8
23.4
34.4
10.6
Anti Diabetic
38.2
29.5
29.4
36.9
3.5
Gastro Intestinal
25.4
23.0
10.2
25.1
1.3
Vitamins
15.8
16.8
-5.9
15.6
1.3
Neuro
14.4
14.0
2.9
13.8
4.4
Pain
13.2
12.8
3.3
12.7
3.4
Gynaecological
11.4
9.8
16.7
10.7
6.8
2.0
1.8
12.6
2.0
0.9
Ophthal
Page 9
Cadila Healthcare
Stock Performance
Acute,
933.57,
31.3%
Chronic,
1428.21,
47.9%
SubChronic,
617.73,
20.7%
140
120
100
80
60
Sep-15
Nov-15
Jan-16
Mar-16
May-16
CNX Pharma
Jul-16
Sep-16
Cadila Healthcare
11 to 20
21 to 30
31 to 50
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
15.8
14.9
Others
6.4
8.2
6.7
7.0
8.4
4.7
7.0
8.8
12.6
12.8
10.1
7.6
2.1
4.1
0
Top 10
Dec-15
13.1
6.3
12.7
9.8
10
9%
10.6
15.8
15
14.2
(%)
11%
13.7
20
20%
13%
Nov-15
23.0
24.9
30
25
47%
Oct-15
Aug-15
Sep-15

Cadila Healthcare
4.2
4.1
4.0
3.9
3.8
3.7
3.6
3.5
3.4
4.1
3.9
4.0
4.0
3.9 3.9
3.9
3.9 3.9
3.9
3.8
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
3.7 3.6
Aug-15
(%)
Cadila Healthcare
Brand
Therapy
Skinlite
Derma
Mifegest Kit
Gynaecological
(| crore)

13.9
13.9
0.2
13.3
4.4
9.4
11.2
-16.4
10.7
-12.8
Deriphyllin
Respiratory
9.2
6.5
41.9
8.4
9.8
Pantodac
Gastro Intestinal
9.1
8.0
13.6
10.5
-12.9
Atorva
Cardiac
9.0
10.5
-13.8
8.4
7.3
Falcigo
Anti Malarials
6.5
7.9
-17.7
5.7
14.4
Zyrop
Blood Related
6.5
5.8
12.2
6.9
-6.5
Vivitra
Anti-Neoplastics
5.7
0.0
NA
6.4
-10.3
Thrombophob
Pain
5.6
4.7
20.0
5.0
12.8
Sovihep
Anti-Infectives
5.5
5.2
6.9
5.2
6.7
Cardiac
16%
Other
39%
Gastro
Intestinal
14%
Respiratory
11%
Pain
10%
Gynaecological
10%
(| crore)
Therapy
Aug' 16
Aug' 15
YoY (%)
July' 16
Cardiac
52.8
54.3
-2.6
51.4
MoM (%)
2.9
Gastro Intestinal
47.4
44.4
6.8
48.4
-2.0
13.4
Respiratory
38.5
31.3
22.7
33.9
Gynaecological
31.9
35.3
-9.7
32.8
-2.9
Pain
36.1
31.4
15.1
32.7
10.5
Derma
26.9
25.0
7.8
25.3
6.3
Anti-Infectives
30.9
27.1
14.2
28.0
10.4
-0.3
Anti-Neoplastics
23.0
21.3
7.9
23.0
Vitamins
17.5
13.3
30.9
16.7
4.4
8.3
10.1
-17.8
7.3
14.6
Anti Malarials
Page 10
GlaxoSmithKline
Stock Performance
Chronic,
411.83,
12.9%
Acute,
2117.94,
66.3%
140
120
100
80
60
SubChronic,
664.88,
20.8%
Sep-15
Nov-15
Jan-16
Mar-16
May-16
CNX Pharma
Jul-16
Sep-16
GSK Pharma
21 to 30
31 to 50
Aug-16
6.4
7.2
14.9
15.8
Jul-16
Jun-16
-6.7
0.3
-9.5

11 to 20
6.7
8.8
4.7
7.0
-10
-15
Top 10
May-16
Apr-16
Mar-16
Feb-16
12.6
2.2
6.9
10.1
13.1
Jan-16
Dec-15
Nov-15
23.0
Oct-15
-7.2
-5
16%
4.7
-1.1
9%
1.2
(%)
51%
9.8
10
10%
4.5
15
14%
10.6
20
13.7
25
21.2
Aug-15
Sep-15

Glaxosmithkline Pharmaceuticals
Others

3.6
3.5
3.4
3.3
3.4 3.4
3.3
3.1 3.1
3.0
3.0 3.0
3.0
2.9
2.8
3.0
(| crore)
Brand
Therapy
Augmentin
Anti-Infectives
25.7
27.2
-5.6
20.9
Calpol
Pain
23.5
14.9
57.8
23.4
0.7
Synflorix
Vaccines
18.3
14.6
25.0
16.2
13.1
Zinetac
Gastro Intestinal
13.1
12.6
3.4
14.8
-11.6
22.8
12.1
-16.6
9.2
9.6
Betnovate N
Derma
8.6
12.2
-29.2
9.2
-5.6
Betnesol
Hormones
8.6
8.0
7.4
8.1
6.0
T Bact
Derma
8.1
7.9
3.2
9.3
-12.5
Aug-16
10.1
Jun-16
Derma
May-16
Betnovate C
Apr-16
2.4
-5.1
Mar-16
7.3
12.2
Feb-16
11.4
2.8
Jan-16
9.9
11.3
Dec-15
11.1
11.6
Nov-15
12.2
Hormones
Oct-15
Anti-Infectives
Eltroxin
Sep-15
Ceftum
Aug-15
2.6
Jul-16
(%)
3.2
3.4
Glaxosmithkline Pharmaceuticals

Other
26%
Anti-Infectives
23%
Respiratory
8%
Pain
10%
Derma
18%
Vaccines
15%

Therapy
(| crore)
Aug' 16
Aug' 15
YoY (%)
July' 16
Anti-Infectives
66.7
66.1
0.9
61.2
MoM (%)
9.0
Derma
45.4
53.3
-15.0
46.0
-1.4
Vaccines
43.2
34.6
24.6
39.9
8.2
Pain
34.5
25.5
35.4
34.9
-1.0
Respiratory
23.0
20.9
9.9
20.8
10.4
Hormones
20.9
20.1
4.4
21.0
-0.3
Vitamins
23.4
22.2
5.7
24.0
-2.6
Gastro Intestinal
-10.7
14.9
15.2
-1.8
16.7
Cardiac
4.5
6.1
-26.6
4.6
-3.3
Gynaecological
2.2
2.8
-21.5
3.4
-34.1
Page 11
Wockhardt
Stock Performance
Chronic,
223.03,
19.3%
Acute,
803.34,
69.7%
400
350
300
250
200
150
100
50
0
SubChronic,
126.85,
11.0%
Sep-15
Nov-15
Jan-16
Mar-16
May-16
CNX Pharma
Jul-16
Sep-16
Wockhardt
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Aug-15
Sep-15
60
11 to 20
21 to 30
31 to 50
Others
15.8
9.2
14.9
14.4
6.7
8.8
9.4
1.8
2.5
0
Top 10
4.7
4.9
7.0
12.6
5.5
23.0
38.3
13.1
10.1
9.9
10
9.8
20
15%
13.7
24.7
54%
10.6
30
(%)
9%
42.6
40
8%
29.8
50.5
50
14%
Wockhardt

Brand
1.8
1.7
1.6
1.5
1.4
1.3
1.2
1.1
1.0
Therapy
Practin
1.28
1.29
Aug-16
Jul-16
Jun-16
1.28 1.25
1.22
May-16
Apr-16
Mar-16
Feb-16
1.37 1.37 1.34

1.33
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
1.35
1.39 1.41 1.38
Wockhardt
Intestinal
25%
Vitamins
15%
Anti-Infectives
7%
Neuro
8%
Vitamins
27.0
22.9
18.1
25.6
5.4
7.6
6.2
21.8
7.3
4.8
Tryptomer
Neuro
5.7
5.8
-0.2
5.1
12.9
Wepox
Blood Related
5.6
0.7
644.5
6.0
-6.3
Bro Zedex
Respiratory
4.8
3.5
37.9
4.7
2.7
Methycobal
Vitamins
4.5
4.6
-3.8
4.3
4.8
Biovac A
Vaccines
4.1
5.5
-24.7
2.7
52.3
Zedex
Respiratory
3.4
2.4
41.9
3.4
1.3
Biovac V
Vaccines
3.4
5.7
-40.0
3.5
-1.4
Wosulin
Anti Diabetic
2.7
2.0
32.7
2.3
15.5
Exhibit 38: Contribution of therapies to domesticGastro

sales (MAT Aug16)
Other
33%
(| crore)
Spasmo Proxyvon PluGastro Intestinal
Aug-15
(%)
Respiratory
12%

Therapy
(| crore)
Aug' 16
Aug' 15
YoY (%)
July' 16
Gastro Intestinal
29.4
25.2
16.5
28.1
MoM (%)
4.5
Vitamins
19.4
17.9
8.5
18.5
5.3
Respiratory
2.2
15.7
10.4
51.7
15.4
Neuro
9.7
9.5
1.9
8.9
7.9
Anti-Infectives
8.6
8.7
-0.9
7.5
15.6
Anti Diabetic
8.0
7.0
14.9
7.2
11.3
Derma
8.3
7.4
12.1
7.4
12.6
Pain
6.3
8.4
-25.5
5.9
6.0
Vaccines
7.7
11.2
-31.4
6.2
24.2
Hormones
2.5
1.9
30.5
2.6
-3.1
Page 12
Glenmark Pharmaceuticals
Stock Performance
200
180
160
140
120
100
80
60
Chronic,
781.54, 37.2%
Sub-Chronic,
473.14, 22.5%
Acute, 844.70,
40.2%
Sep-15
Nov-15
Jan-16
Mar-16
May-16
CNX Pharma
Jul-16
Sep-16
Glenmark
11 to 20
21 to 30
31 to 50
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
43.6
15.8
19.7
14.9
15.8
7.1
6.7
8.8
8.9
7.0
14.8
12.6
19.6
10.1
16.3
9.8
13.1
18.6
23.0
Top 10
4.7
8.6
12%
10%
11.5
13%
(%)
36%
10.6
29%
50
45
40
35
30
25
20
15
10
5
0
13.0
13.7
28.0
Sep-15
Aug-15
Others

Therapy
Telma
Cardiac
13.6
14.0
-3.0
12.5
Telma H
Cardiac
12.9
11.2
16.1
11.9
8.7
Ascoril Plus
Respiratory
11.4
7.1
59.8
10.0
14.1
Candid
Derma
9.1
7.6
20.1
10.0
-9.1
2.1
Candid-B
Derma
8.6
7.6
13.7
9.6
-10.5
Telma Am
Cardiac
6.9
5.9
15.8
6.4
7.0
1.9
Ascoril Ls
Respiratory
5.5
3.2
72.9
4.0
39.2
Onabet
Derma
4.9
3.2
49.8
Zitamet Plus
Anti Diabetic
3.8
0.0 NA
Lizolid
Anti-Infectives
3.5
2.7
2.7
2.5
2.3
2.3
2.4
2.6
2.5 2.5
2.5
2.4 2.4
2.4
2.4
2.3 2.3
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
2.2
Aug-15
(%)
(| crore)
Brand

Anti Diabetic
8%
Derma
29%
Anti-Infectives
13%
Respiratory
16%
32.6
9.1
4.2
15.1
3.5
8.1
2.9
22.9
Other
12%
Cardiac
22%

Therapy
(| crore)
Aug' 16
Aug' 15
YoY (%)
July' 16
Derma
63.2
56.1
12.8
61.3
MoM (%)
3.1
Cardiac
47.4
43.0
10.2
43.8
8.2
Respiratory
40.4
25.6
57.7
33.6
20.2
Anti-Infectives
36.9
28.1
31.4
32.0
15.5
Anti Diabetic
6.7
14.7
17.7
-17.1
13.7
Vitamins
5.2
5.7
-8.7
5.1
1.8
Gastro Intestinal
8.1
4.7
72.1
6.8
19.2
Gynaecological
5.9
4.7
26.3
5.9
-0.6
Pain
4.1
4.4
-7.2
3.9
5.8
Ophthal
4.4
3.9
15.2
3.9
14.4
Page 13
Torrent Pharmaceuticals
Stock Performance
Chronic,
1069.36,
50.1%
200
160
120
80
40
SubChronic,
509.42,
23.9%
Acute,
555.14,
26.0%
Sep-15
Nov-15
Jan-16
May-16
CNX Pharma
Jul-16
Sep-16
Torrent Pharma
Others
Aug-16
15.8
14.9
6.7
8.8
2.4
1.4
7.3
4.7
7.0
2.4
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
12.6
10.2
-5
-2.7
31 to 50
-3.0
21 to 30
10.1
13.1
0
11 to 20
Jan-16
Dec-15
Nov-15
5.4
9%
7.4
10
3.8
14%
12%
9.8
(%)
15
10.6
16.0
20
33%
13.7
21.7
32%
19.9
25
23.0Oct-15
Aug-15
Sep-15
Top 10
Mar-16
2.4
2.4
2.34
2.29
2.3
2.24
2.2
2.22
2.16
2.2
2.19
2.25
2.22
2.29
2.24
2.21
2.19
Therapy
Shelcal
Vitamins
17.5
14.5
20.4
17.6
Chymoral Forte
Pain
11.2
11.9
-5.6
10.6
6.2
Nikoran
Cardiac
7.6
7.2
5.8
7.2
6.4
Azulix-Mf
Anti Diabetic
6.1
4.5
36.9
5.7
7.1
-0.6
5.3
4.1
30.5
5.5
-2.9
Gastro Intestinal
4.7
3.9
19.1
4.6
2.2
Jan-16
Aug-16
Gastro Intestinal
Nexpro
Jul-16
Nexpro Rd
Jun-16
2.1
May-16
-1.2
Apr-16
7.2
5.5
Mar-16
5.3
10.9
Feb-16
19.9
4.9
Dec-15
4.7
5.4
Oct-15
5.7
Cardiac
Sep-15
Cardiac
Dilzem
Aug-15
Nebicard
2.1
Nov-15
(%)
2.3
2.32
(| crore)
Brand
Cardiac
29%
Pain
8%
Gastro
Intestinal
15%
Vitamins
16%
Vitamins
4.5
3.2
37.2
4.5
-0.3
Rozucor
Cardiac
3.6
3.1
16.3
3.3
7.1

Other
16%
Shelcal Ct
Neuro
16%
(| crore)
Therapy
Aug' 16
Aug' 15
YoY (%)
July' 16
MoM (%)
Cardiac
58.6
Neuro
33.9
54.3
8.1
56.7
3.4
30.1
12.4
32.4
Vitamins
4.5
33.8
27.5
23.0
33.9
-0.2
Gastro Intestinal
31.9
26.8
18.8
32.0
-0.3
Pain
17.8
16.9
4.9
16.9
5.4
Anti Diabetic
13.8
10.9
26.9
13.0
6.0
Anti-Infectives
8.7
9.3
-7.0
7.9
9.1
Derma
5.9
4.4
35.5
5.6
4.9
Gynaecological
3.0
3.2
-5.5
2.9
6.5
Urology
1.0
0.8
33.1
1.0
-1.9
Page 14
Ipca Laboratories
Stock Performance
150
125
100
75
50
Chronic,
325.51,
27.3%
Acute,
797.43,
66.9%
SubChronic,
68.40,
5.7%
Sep-15
Nov-15
Jan-16
Mar-16
May-16
CNX Pharma
Jul-16
Sep-16
Ipca
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Aug-15
Sep-15

34.5
40
35
31 to 50
15.8
27.7
14.9
6.7
4.0
3.7
Ipca Laboratories
3.3
21 to 30
1.5
11 to 20
4.7
7.0
11.5
Top 10
8.8
12.6
10.1
13.1
11.8
9.1
3.0
16%
9.8
10
6.3
15
10.6
20
3.5
38%
13.7
(%)
25
12%
11%
23.0
25.8
30
23%
Others
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
1.3 1.2 1.2 1.2

1.2 1.2 1.2 1.2
1.4
1.5
Aug-16
1.4 1.4
Nov-15
Sep-15
1.3
Oct-15
2.0
1.8
1.6
1.4
1.2
1.0
0.8
0.6
Aug-15
(%)
Ipca Laboratories
Pain
25%
Anti-Infectives
6%
Gastro
Intestinal
8%
Brand
Therapy
Zerodol P
Pain

9.6
6.6
43.9
5.7
67.4
Rapither-Ab
Anti Malarials
9.2
3.8
139.9
7.0
30.6
Zerodol Sp
Pain
8.5
8.2
4.3
8.4
1.2
Larinate
Anti Malarials
8.2
4.3
89.9
6.0
37.4
Lariago
Anti Malarials
7.5
3.1
138.6
5.0
49.9
Hcqs
Anti Malarials
5.1
4.9
3.0
5.2
-2.6
Lumerax
Anti Malarials
4.6
3.0
55.7
3.4
36.8
Glycinorm M
Anti Diabetic
3.3
2.8
20.0
3.6
-7.1
Folitrax
Anti-Neoplastics
3.1
2.5
22.3
3.0
3.3
Malirid
Anti Malarials
2.5
1.5
66.9
2.0
28.3

Other
24%
(| crore)
Anti Malarials
20%
Cardiac
17%

Therapy
(| crore)
Aug' 16
Aug' 15
YoY (%)
July' 16
Pain
34.6
29.0
19.3
29.8
MoM (%)
16.4
Anti Malarials
39.4
22.5
75.0
30.7
28.4
Cardiac
19.2
18.2
5.3
18.9
1.5
Gastro Intestinal
9.4
8.9
5.5
9.6
-2.3
Anti-Infectives
8.6
7.5
14.1
7.3
17.6
Anti Diabetic
6.1
5.6
10.3
6.3
-3.1
Respiratory
5.7
4.4
30.2
4.8
20.1
Anti-Neoplastics
5.0
4.0
26.0
4.7
5.6
Neuro
5.0
4.1
21.9
4.4
13.7
Derma
4.1
3.2
30.0
3.9
6.6
Page 15
Biocon
Stock Performance
Chronic,
234.38,
72.0%
140
120
100
80
SubChronic,
23.33,
7.2%
Acute,
68.01,
20.9%
60
Sep-15
Nov-15
Mar-16
May-16
Jul-16
Sep-16
Biocon
31 to 50
Aug-16
14.9
15.8
Jul-16
Jun-16
May-16
Apr-16
Mar-16
8.8
3.5
6.7
8.8
9.4
4.7
7.7
7.0
12.6
11.3
14.5
Feb-16
Jan-16
10.1
13.1
Dec-15
Nov-15
0.1
-10
Others
-0.8
-5
-11.2
21 to 30
23.0
Oct-15
2%
11 to 20
5.3
(%)
5.2
10
5%
5%
9.8
15
10%
7.3
78%
13.7
20
10.6
25
10.0
Aug-15
Sep-15
Top 10
Jan-16
CNX Pharma
-15
Biocon

0.39
Brand
0.38
0.37
0.36
0.35
0.33
0.33
0.33
0.34 0.34 0.35
0.34
0.34
Therapy
(| crore)
Insugen
Anti Diabetic
7.7
7.2
6.3
7.1
7.8
Basalog
Anti Diabetic
5.6
4.7
18.6
5.5
2.6
2.3
1.8
Erypro
Blood Related
2.4
2.0
19.2
Biomab Egfr
Anti-Neoplastics
1.9
0.2
938.6
0.29
Canmab
Anti-Neoplastics
1.8
1.7
4.4
1.7
6.1
0.27
Abraxane
Anti-Neoplastics
1.7
1.0
68.9
2.3
-27.7
Insugen R
Anti Diabetic
1.5
1.5
4.3
1.4
13.0
Blisto Mf
Anti Diabetic
1.3
1.4
-9.6
1.2
7.5
Insugen N
Anti Diabetic
0.6
0.8
-19.4
0.5
32.0
Psorid
Anti-Neoplastics
0.6
0.7
-10.4
0.7
-6.7
0.32
0.32
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
0.31
Jan-16
Dec-15
Nov-15
Sep-15
Oct-15
0.31
0.31
Aug-15
(%)
Biocon

Cardiac
5%
Blood Related
6%
Derma
3%
AntiNeoplastics
23%
0.1 1284.8
Other
4%

Therapy
Anti Diabetic
Anti-Neoplastics
Anti Diabetic
59%
(| crore)
Aug' 16
Aug' 15
YoY (%)
July' 16
17.9
7.4
MoM (%)
16.9
6.3
16.8
6.5
5.1
44.6
6.2
19.3
Blood Related
2.4
2.0
21.7
2.4
1.9
Cardiac
1.3
1.3
-5.8
1.2
2.2
Derma
0.7
0.7
0.9
0.8
-7.8
Anti-Infectives
0.5
0.7
-24.6
0.6
-16.1
Others
0.2
0.2
17.4
0.2
-4.5
Gastro Intestinal
0.1
0.4
-74.5
0.1
-13.2
Vitamins
0.1
0.2
-40.8
0.1
-16.3
Pain
0.0
0.0
3.8
0.1
-61.7
Page 16
Pfizer
Stock Performance
Chronic,
433.18,
15.7%
SubChronic,
564.23,
20.5%
Acute,
1754.51,
63.8%
200
160
120
80
40
Sep-15
Nov-15
Jan-16
Mar-16
May-16
CNX Pharma
Pfizer
21 to 30
31 to 50
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
15.8
5.8
14.9
8.9
6.7
-1.0
7.2
2.7
3.4
4.7
7.0
8.8
12.6
5.1
-3.5
-5
11 to 20
Feb-16
Jan-16
Dec-15
10.1
9.8
13.1
25.0
1.6
19%
3.3
(%)
10
10.6
15
50%
10%
8.9
20
10%
13.7
18.5
25
11%
Nov-15
23.0
30
Oct-15
Sep-15
Aug-15
-10
Others
Pfizer

3.0
2.93
2.90
2.93
2.8
2.95
2.90 2.91 2.92

2.83
2.88
2.84
(%)
2.73
2.79
2.72
2.6
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
2.4
Aug-15
Sep-16
Top 10
Jul-16
Pfizer
(| crore)
Brand
Therapy
Corex
Respiratory
24.4
27.4
-11.0
24.1
1.1
Becosules
Vitamins
20.8
21.7
-4.5
21.5
-3.2
Minipress Xl
Cardiac
13.1
9.6
36.9
16.3
-19.9
Magnex
Anti-Infectives
12.7
12.3
3.1
11.9
6.6
Gelusil Mps
Gastro Intestinal
12.3
11.6
5.6
12.3
0.0
Dolonex
Pain
12.1
11.4
5.7
12.8
-6.1
Mucaine
Gastro Intestinal
10.5
8.9
17.3
10.2
2.5
Wysolone
Hormones
10.4
9.0
15.1
9.6
7.8
Prevenar 13
Vaccines
7.1
3.0
133.8
6.0
17.8
Dalacin C
Anti-Infectives
6.6
6.6
0.6
5.7
16.8
Anti-Infectives
16%
Other
40%
Respiratory
14%
Gastro
Intestinal
11%
Hormones
9%
Vitamins
10%
Therapy
(| crore)
Aug' 16
Aug' 15
YoY (%)
July' 16
Anti-Infectives
37.7
39.6
-4.7
35.0
MoM (%)
7.9
Respiratory
33.5
32.6
2.8
31.6
6.0
Gastro Intestinal
27.6
25.7
7.5
27.7
-0.5
Vitamins
27.3
27.5
-0.8
27.9
-2.1
Hormones
23.7
22.0
7.4
22.2
6.4
Gynaecological
21.1
17.8
18.9
20.8
1.6
Neuro
16.4
17.1
-4.3
14.8
10.4
Cardiac
19.1
15.3
24.4
21.9
-12.8
Pain
17.3
15.9
8.8
16.9
2.2
Vaccines
12.3
6.9
77.7
11.2
9.6
Page 17
Novartis
Stock Performance
Chronic,
414.61,
41.3%
190
140
SubChronic,
162.81,
16.2%
Acute,
427.68,
42.6%
90
40
Sep-15
Nov-15
Jan-16
Mar-16
May-16
CNX Pharma
Novartis India
31 to 50
Aug-16
Jul-16
Jun-16
15.8
14.9
2.9
4.4
3.9
Others
Novartis India
1.3
1.21
1.2
1.16 1.17 1.16 1.15
1.15 1.16
1.19 1.19
1.1
1.10 1.10
1.06
1.02
1.1
Brand
Therapy
Galvus Met
Anti Diabetic
(| crore)

27.0
24.7
9.2
26.6
1.2
Voveran
Pain
19.7
14.9
32.7
18.6
6.1
Galvus
Anti Diabetic
10.1
10.3
-2.6
9.6
5.0
Rabipur (Novartis)
Vaccines
8.2
7.0
16.5
5.6
45.7
6.2
Tegrital
Neuro
4.4
4.5
-2.5
4.2
1.0
Voveran
Pain
3.5
3.1
13.7
3.4
3.5
0.9
Regestrone
Gynaecological
2.5
2.9
-12.9
2.9
-14.1
Methergin
Gynaecological
2.4
3.0
-20.6
2.3
3.8
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
Aug-15
1.0
Aug-16
(%)
6.7
4.7
5
21 to 30
8.8
10.2
18.7
21.6
12.6
10.1
14.9
13.1
17.3
20.4
9.8
10
7.0
79%
15
10.6
15.3
(%)
20
13.7
21.7
25
25.1
23.0
27.4
30
2%
11%4%4%
11 to 20
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Aug-15
Sep-15
1.2
Sep-16
Top 10
Jul-16
Novartis India
Syntocinon
Gynaecological
2.4
2.2
9.0
2.2
6.0
Pybactum
Anti-Infectives
2.0
0.5
273.4
0.2
712.6
Exhibit 68: Contribution of Other

therapies to domestic sales (MAT Aug16)
15%
Therapy
Gynaecological
8%
Anti Diabetic
35%
Vaccines
9%
Vitamins
10%
Pain
23%
(| crore)
Aug' 16
Aug' 15
YoY (%)
July' 16
MoM (%)
Anti Diabetic
37.6
35.7
5.3
36.8
2.2
Pain
24.6
19.8
24.5
23.4
5.3
Vitamins
8.8
9.9
-10.8
8.8
0.2
Vaccines
8.3
7.1
16.3
5.7
45.8
Gynaecological
7.4
8.3
-11.4
7.6
-2.8
Neuro
4.4
5.6
-20.5
4.2
6.2
Anti-Infectives
5.4
4.6
16.0
3.2
70.8
Respiratory
1.9
1.8
10.7
1.8
10.5
Anti-Neoplastics
0.5
0.5
2.5
0.4
33.7
Cardiac
0.7
1.2
-39.1
0.7
2.2
Page 18
Unichem Laboratories
Stock Performance
Chronic,
472.89,
56.7%
160
130
100
70
Sep-15
SubChronic,
48.43,
5.8%
Jan-16
Mar-16
May-16
CNX Pharma
Jul-16
Sep-16
Unichem Labs
11 to 20
21 to 30
31 to 50
14.9
4.0
8.4
6.7
8.8
2.3

Brand
1.10
1.00
0.94
0.90
0.94
0.89 0.90 0.90
0.89
0.95
0.92
0.92
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
0.84 0.85
Nov-15
Oct-15
Sep-15
0.84 0.82
Aug-15
4.7
(%)
Others
0.80
0.6
3.1
Top 10
7.0
9.9
12.6
10.1
13.1
3.8
2.7
10.0
14%
9%
13.5
12%
11.3
10
9.8
15
10.6
(%)
33%
13.7
20
15.8
19.9
23.0
28.3
30
25
32%
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Oct-15
Aug-15
Nov-15
Sep-15
Acute,
312.14,
37.5%
Nov-15
Other
11%
Gastro
Intestinal
12%
Neuro
14%
(| crore)
Losar H
Cardiac
8.4
6.2
36.6
8.3
1.3
Ampoxin
Anti-Infectives
7.4
5.8
28.0
6.8
8.6
Losar
Cardiac
5.9
5.0
16.7
5.6
5.9
Unienzyme
Gastro Intestinal
5.5
4.6
18.7
5.3
3.5
Vizylac
Gastro Intestinal
3.5
3.1
14.2
3.2
10.7
Arkamin
Cardiac
2.1
1.2
86.0
2.1
0.1
Serta
Neuro
2.0
1.6
22.3
1.9
7.6
Trika
Neuro
1.9
2.1
-8.3
1.9
-1.4
Unistar (Unichem)
Cardiac
1.7
1.4
23.8
1.6
9.4
Linox
Anti-Infectives
1.7
0.9
90.4
1.5
8.6

Pain
4%
Therapy
Cardiac
42%
Anti-Infectives
17%
(| crore)
Therapy
Aug' 16
Aug' 15
YoY (%)
July' 16
MoM (%)
Cardiac
34.8
28.5
22.1
34.2
1.8
Anti-Infectives
16.3
12.3
32.9
14.9
9.8
Neuro
11.9
9.3
28.9
11.2
6.9
Gastro Intestinal
10.7
9.1
18.4
10.1
6.6
Pain
4.0
3.0
33.9
4.0
1.0
Anti Diabetic
3.8
2.2
70.8
3.5
10.1
Respiratory
2.2
1.7
30.7
2.1
6.3
Vitamins
2.1
1.9
9.9
1.9
6.9
Derma
2.0
1.4
42.4
1.8
13.1
Gynaecological
0.4
0.5
-25.4
0.4
-7.9
Page 19
Indoco Remedies
Stock Performance
140
120
100
80
60
Chronic,
43.70,
6.5%
Acute,
547.10,
81.8%
Sep-15
SubChronic,
77.72,
11.6%
Nov-15
Jan-16
Mar-16
May-16
CNX Pharma
Jul-16
Sep-16
Indoco
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Aug-15
Sep-15
40.9
50
11 to 20
21 to 30
31 to 50
-10
Others
15.8
14.9
6.7
11.5
8.8
5.2
0.7
4.7
7.0
12.6
5.6
5.4
10.1
13.1
11.0
0.9
0.8 0.8
0.8
0.8
0.7 0.7
0.7 0.7
0.7 0.7 0.7
0.7
0.7
0.7
0.6
0.7
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
0.6
Aug-15
Indoco Remedies
(%)
9.8
0.7
-0.9
-1.3
10.3
15%
Top 10
23.0
10
10.6
9%
20
-6.4
48%
13.7
10%
(%)
30
16.2
18%
34.0
40
Indoco Remedies
Brand
Therapy
Febrex Plus
Respiratory
(| crore)

10.8
5.3
106.0
9.0
20.5
Oxipod
Anti-Infectives
6.3
3.0
110.9
5.0
27.9
Cyclopam
Gastro Intestinal
4.6
4.1
12.7
5.6
-17.0
Atm
Anti-Infectives
3.7
2.4
54.6
3.0
20.9
-12.5
Sensodent-K
Stomatologicals
3.2
2.7
21.8
3.7
Cital
Urology
2.9
2.6
8.9
2.7
5.8
Cyclopam
Gastro Intestinal
2.5
1.8
39.4
3.0
-17.2
Cloben G
Derma
2.3
2.0
18.8
2.2
5.6
Karvol Plus
Respiratory
2.2
1.5
48.1
1.9
14.4
Sensodent-Kf
Stomatologicals
1.8
2.0
-8.3
2.1
-10.1

Other
25%
Respiratory
19%
Anti-Infectives
19%
Vitamins
7%
Gastro
Intestinal
14%
Stomatological
s
16%

Therapy
(| crore)
Aug' 16
Aug' 15
YoY (%)
July' 16
MoM (%)
17.4
9.8
78.2
14.5
20.2
Anti-Infectives
16.7
10.5
58.1
13.8
20.3
Stomatologicals
10.5
9.2
13.8
11.7
-10.3
Gastro Intestinal
Respiratory
10.5
8.8
20.3
12.2
-13.8
Vitamins
5.5
4.3
26.4
5.3
3.0
Urology
3.3
3.0
11.8
3.2
6.1
Ophthal
3.5
3.1
13.5
3.1
12.6
Pain
3.0
2.4
23.9
3.0
-0.2
Derma
3.1
2.6
17.2
2.9
4.5
Anti Diabetic
2.2
1.8
17.9
2.2
-0.7
Page 20
Ajanta Pharmaceuticals
Stock Performance
Chronic,
215.14,
48.4%
290
240
190
140
90
40
SubChronic,
52.76,
11.9%
Acute,
176.88,
39.8%
Sep-15
Nov-15
Jan-16
Mar-16
May-16
CNX Pharma
Ajanta
23%
21 to 30
31 to 50
Others
0.5
0.51
0.5
0.51
Aug-16
Jul-16
Jun-16
15.8
14.9
10.9
6.7
0.51 0.50
0.50
0.49
0.48
0.48 0.48
0.460.46
0.46
0.45
0.4
0.4
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
0.4
Sep-15
Ajanta Pharma
Aug-15
11.4
13.1
(%)
8.8
4.7
7.6
7.0
7.6
12.6
10.5
0.5
May-16
Apr-16
Mar-16
Feb-16
Jan-16
10.1
6.9
6.5
5
11 to 20
Dec-15
13.1
14.3
9.8
10
12%
9.9
(%)
10.6
12.6
15
13%
10%
Nov-15
13.7
18.3
20
42%
11.9
25
23.0Oct-15
Aug-15
Sep-15
0.5
Sep-16
Top 10
Jul-16
Ajanta Pharma
(| crore)
Brand
Therapy
Met Xl
Cardiac
4.4
3.9
11.7
4.3
1.3
Melacare
Derma
3.2
3.4
-6.6
3.8
-16.4
Atorfit Cv
Cardiac
3.1
3.3
-3.6
2.9
9.2
Rosufit Cv
Cardiac
1.6
1.1
44.4
1.4
13.5
Feburic
Pain
1.4
1.3
13.8
1.3
10.1
Soft Drops
Ophthal
1.3
1.2
5.6
1.4
-4.1
Met Xl Am
Cardiac
1.2
0.9
33.4
1.2
6.6
Cinod
Cardiac
1.0
0.7
34.2
0.9
15.7
Rosutor Gold
Cardiac
0.9
0.6
44.6
0.9
-1.8
Peroclin
Derma
0.8
0.8
1.4
0.7
12.1
Pain
5%
Others
9%
Cardiac
34%
Vitamins
6%
Derma
22%
Ophthal
24%
(| crore)
Therapy
Aug' 16
Aug' 15
YoY (%)
July' 16
Cardiac
16.2
13.7
17.9
15.2
MoM (%)
6.7
Ophthal
10.2
9.6
5.4
10.2
-0.5
Derma
8.9
8.7
2.7
8.9
-0.1
Vitamins
2.2
2.5
-13.3
2.0
8.2
Pain
2.2
2.2
-0.3
2.0
6.0
Gastro Intestinal
1.0
1.1
-8.9
0.9
4.1
Neuro
1.0
0.8
12.9
0.8
12.5
Anti-Infectives
1.0
0.7
40.7
0.8
19.6
Anti Diabetic
0.8
0.0
1850.1
0.7
14.5
Respiratory
0.3
0.3
-3.6
0.3
9.3
Page 21
Alembic Pharmaceuticals
Stock Performance
200
180
160
140
120
100
80
60
40
Chronic
231.46,
18.8%
SubChronic
214.35,
17.4%
Sep-15
Nov-15
Jan-16
Mar-16
CNX Pharma
May-16
Jul-16
Sep-16
Alembic Pharma
Aug-16
Jul-16
Jun-16
May-16
Apr-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
Aug-15

Mar-16
Acute,
784.06,
63.8%
11 to 20
21 to 30
31 to 50
Others
28.0
15.8
14.9
11.4
6.7
8.8
11.3
4.7
5.6
8.1
7.0
12.6
13.7
23.3
24.1
13.1
19.0
6.0
5
Top 10
10.1
10
9.8
(%)
15
12%
10.6
20
13%
13.7
21.3
25
42%
10%
23.0
31.5
30
23%
29.3
35
Alembic Pharma

Brand
Therapy
Azithral
Anti-Infectives
14.3
11.6
Althrocin
Anti-Infectives
8.9
Roxid
Anti-Infectives
5.7
Gestofit
Gynaecological
Wikoryl
Respiratory
1.3
Ulgel
1.2
1.6
1.5
1.49 1.49 1.49

1.43
1.43
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
Aug-15
1.3
1.31 1.30 1.32
Aug-16
1.36
1.4
Jul-16
1.4
1.42 1.44
Jun-16
1.41
1.47
May-16
1.5
(%)
(| crore)
Alembic Pharma

23.8
12.1
8.3
6.9
8.5
4.5
4.7
21.2
4.6
25.3
5.1
4.4
17.3
5.4
-5.4
5.1
2.9
72.8
4.2
21.0
Gastro Intestinal
3.4
3.3
3.2
3.4
0.4
Rekool D
Gastro Intestinal
2.9
3.1
-4.3
3.1
-4.9
Richar
Gynaecological
2.7
2.0
34.8
2.7
2.1
Glisen Mf
Anti Diabetic
2.3
2.2
4.3
2.3
-1.8
Rekool
Gastro Intestinal
2.1
2.2
-5.1
2.3
-9.7
Other
25%
Anti-Infectives
23%
Gynaecological
11%
Respiratory
13%
Gastro
Intestinal
14%
Cardiac
14%
Therapy
Anti-Infectives
Cardiac
Gastro Intestinal
Respiratory
Gynaecological
Vitamins
Anti Diabetic
Pain
Urology
Derma
Aug' 16
34.5
18.8
18.7
19.4
14.9
11.0
9.0
5.1
3.1
2.3
Aug' 15
29.3
15.8
17.6
13.6
12.5
8.6
6.6
4.3
2.1
2.6
(| crore)
YoY (%)
17.7
19.3
6.5
41.9
19.9
27.7
37.6
18.9
46.5
-13.2
July' 16
29.7
18.1
18.8
15.8
14.8
11.1
8.7
4.6
2.8
2.1
MoM (%)
16.1
3.7
-0.8
22.3
0.7
-0.4
3.3
11.4
9.5
5.9
18.9
Page 22
ICICIdirect.com coverage universe (Healthcare)

CMP
(|)
TP
(|)
Ajanta Pharma
AJAPHA 1966 1,780 Hold
17298.3
45.4
52.8
63.6
43.3
37.2
30.9
29.9
25.0
21.2
42.9
37.1
35.0
34.2
30.2
Apollo Hospitals
APOHOS 1299 1,440 Hold
18069.6
22.2
18.5
28.7
58.5
70.2
45.3
27.8
27.9
22.5
8.2
7.3
9.6
8.9
7.0
9.9
Aurobindo Pharma
AURPHA
Buy
47126.6
33.9
41.3
48.0
23.7
19.5
16.8
25.0
20.5
17.7
23.3
24.6
25.5
28.1
26.0
23.5
Alembic Pharma
ALEMPHA 652
Hold
12287.4
38.2
20.4
28.1
17.1
32.0
23.2
12.4
23.1
17.5
51.5
23.2
26.2
44.9
20.5
23.5
620
M Cap
(| Cr)
PE(x)
EV/EBITDA (x)
RoCE (%)
RoE (%)
FY17E FY18E FY16 FY17E FY18E FY16 FY17E FY18E FY16 FY17E FY18E
I-Direct
Code
805 1,055
Rating
EPS (|)
FY16 FY17E FY18E FY16
Company
28.2
Biocon
BIOCON
959 1,030
Buy
19184.0
22.5
33.3
38.4
42.6
28.8
25.0
11.5
8.7
7.0
9.1
13.1
14.8
11.1
14.7
15.0
Cadila Healthcare
Cipla
CADHEA
CIPLA
393
602
Buy
Hold
40238.2
48405.4
15.0
18.5
15.8
17.6
20.3
25.4
26.3
32.5
24.9
34.2
19.4
23.7
17.1
20.3
17.5
18.5
13.8
13.7
26.7
12.0
22.9
11.1
26.8
15.2
28.6
12.5
24.7
10.8
25.6
13.8
Divi's Laboratories
DIVLAB
1340 1,415
Buy
35575.4
41.8
45.1
54.5
32.1
29.7
24.6
24.7
21.8
18.1
30.7
29.2
29.8
25.9
23.3
23.4
Dr Reddy's Labs
DRREDD 2974 2,875 Hold
53942.7
142.1
86.5
143.5
20.9
34.4
20.7
13.2
17.6
11.8
17.3
10.9
17.8
20.7
11.4
16.3
Glenmark Pharma
GLEPHA
858 1,000
Buy
25565.9
32.2
41.4
49.8
26.7
20.7
17.2
17.8
14.9
12.1
16.2
18.7
20.6
21.2
21.7
20.9
Indoco Remedies
INDREM
329
Buy
3035.9
9.0
13.6
19.4
36.6
24.3
17.0
17.9
13.5
10.4
12.5
17.3
23.4
14.2
18.3
21.7
Ipca Laboratories
Jubilant Life Sciences
Lupin
405
510
365
IPCLAB
590
605
Buy
7447.1
10.0
21.9
30.2
58.9
27.0
19.5
23.0
14.5
11.5
5.7
11.5
14.4
5.5
11.0
13.5
VAMORG
591
635
Buy
9413.8
26.0
41.4
52.7
22.7
14.3
11.2
10.6
8.7
7.2
12.0
15.1
17.0
14.2
18.8
19.6
1549 1,890
Buy
69859.5
50.4
64.6
75.5
30.7
24.0
20.5
20.2
15.4
12.7
18.6
20.6
22.1
20.7
21.7
20.2
Natco Pharma
NATPHA
LUPIN
647
700
Buy
11273.4
8.9
11.6
13.8
72.7
55.8
46.9
41.7
36.0
30.2
16.0
17.3
18.0
11.9
13.7
14.3
Sun Pharma
SUNPHA
778
890
Buy
187341.7
23.4
29.9
35.5
33.2
26.1
21.9
20.9
16.8
14.2
18.6
20.7
21.2
18.0
19.3
19.2
Syngene International
SYNINT
473
550
Buy
9454.0
11.1
15.8
18.7
42.7
29.9
25.3
26.1
20.8
16.7
13.2
17.4
19.3
21.0
23.6
22.3
Torrent Pharma
TORPHA 1605 1,650
Buy
27159.8
107.8
68.0
74.9
14.9
23.6
21.4
10.5
16.6
15.6
46.7
28.5
27.5
53.8
27.0
24.3
UNILAB
Buy
2434.4
12.3
15.3
21.1
21.8
17.6
12.7
14.9
12.0
8.6
13.8
15.7
18.9
11.7
12.9
15.5
268
340
Exhibit 90: One year forward P/E of CNX Pharma vs. Sensex
45
40
35
30
25
x
20
15
10
5
CNX Pharma
Sep-16
Mar-16
Sep-15
Mar-15
Sep-14
Mar-14
Sep-13
Mar-13
Sep-12
Sep-11
Mar-12
Mar-11
Sep-10
Mar-10
Sep-09
Mar-09
Sep-08
Mar-08
Sep-07
Mar-07
Sep-06
Sensex
Source: Company, ICICIdirect.com Research
Page 23
RATING RATIONALE
ICICIdirect.com endeavours to provide objective opinions and recommendations. ICICIdirect.com assigns

ratings to its stocks according to their notional target price vs. current market price and then categorises them
as Strong Buy, Buy, Add, Reduce and Sell. The performance horizon is two years unless specified and the
notional target price is defined as the analysts' valuation for a stock.
Sector view:
Over weight compared to index
Equal weight compared to index
Under weight compared to index
Index here refers to BSE 500
Pankaj Pandey
Head Research
pankaj.pandey@icicisecurities.com
ICICIdirect.com Research Desk,

ICICI Securities Limited,
1st Floor, Akruti Trade Centre,
Road No. 7, MIDC,
Andheri (East)
Mumbai 400 093
research@icicidirect.com
Page 24
ANALYST CERTIFICATION
We /I, Siddhant Khandekar CA-INTER Mitesh Shah MS (Finance) Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report
accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or
view(s) in this report.
Terms & conditions and other disclosures:

ICICI Securities Limited is a Sebi registered Research Analyst having registration no. INH000000990. ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia,
engaged in the business of stock brokering and distribution of financial products. ICICI Securities is a wholly-owned subsidiary of ICICI Bank which is Indias largest private sector bank and has its various
subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. (associates), the details in respect of which are
available on www.icicibank.com.
ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking
and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts
and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.
The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and
meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without
prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securitiesis is under no obligation to update or keep the information
current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended
temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this
company, or in certain other circumstances.
This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This
report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial
instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their
receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific
circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment
objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate
the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any
loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the
risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to
change without notice.
ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment
in the past twelve months.
ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in
respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.
ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned
in the report in the past twelve months.
ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its analysts did not receive any compensation
or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts have any
material conflict of interest at the time of publication of this report.
It is confirmed that Siddhant Khandekar CA-INTER Mitesh Shah MS (Finance), Research Analysts of this report have not received any compensation from the companies mentioned in the report in the
preceding twelve months.
Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.
ICICI Securities or its subsidiaries collectively or Research Analysts do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the
publication of the research report.
Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject
company/companies mentioned in this report.
It is confirmed that Siddhant Khandekar CA-INTER Mitesh Shah MS (Finance), Research Analysts do not serve as an officer, director or employee of the companies mentioned in the report.
ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.
Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.
We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.
This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution,
publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities
described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and
to observe such restriction.
Page 25

IDirect HealthCheck Sep16

Hochgeladen von

Dokumentinformationen

Originaltitel

Copyright

Verfügbare Formate

Dieses Dokument teilen

Dokument teilen oder einbetten

Freigabeoptionen

Stufen Sie dieses Dokument als nützlich ein?

Sind diese Inhalte unangemessen?

Copyright:

Verfügbare Formate

IDirect HealthCheck Sep16

Hochgeladen von

Copyright:

Verfügbare Formate

Monthly Update

September 21, 2016

Market cap in | crore

On an innovation front, Glenmark has announced the discovery and

In a significant tie-up, Syngene has opened a dedicated centre for US

Syngene opens new centre; Domestic growth

ICICI Securities Ltd. | Retail Equity Research

M&As, Demergers, Tie-ups and JVs

DRL to market three of Amgens Biological drugs in India

ICICI Securities Ltd. | Retail Equity Research

facilities for formulations and three for APIs.

Glenmark announces Initiation of IND studies for GBR 1372

Indoco Goa Plant II received six observations from USFDA

Syngene sets up R&D centre for Amgen in Bengaluru

Apollo Hospital- Lower occupancy, Ind AS hit margins

ICICI Securities Ltd. | Retail Equity Research

Exhibit 2: Patent litigations (12 months)

Source: Bloomberg, ICICIdirect.com Research

ICICI Securities Ltd. | Retail Equity Research

The Indian pharmaceutical market (IPM) grew 15.3% YoY to | 9643

Indian Pharma Market

Source: AIOCD data base, ICICIdirect.com Research

Source: AIOCD data base ; As per AIOCD MAT Aug 2016

Exhibit 4: Companies growth in domestic market in Aug, 2016

Industry acute to chronic therapy ratio percentage

Exhibit 3: Domestic formulations - growth trend

Top brands in Indian pharma market

IPM grew 15% in Aug- highest growth in 9 months

Therapy wise performance (| crore)

Source: AIOCD data base, ICICIdirect.com Research

ICICI Securities Ltd. | Retail Equity Research

Acute : Chronic contribution (MAT Aug16)

Source: NSE, ICICIdirect.com Research

Source: AIOCD data base

Indian Pharma Market

Exhibit 5: Company growth vis--vis Indian pharma market growth

Brands contribution to domestic sales (MAT Aug16)

Sun Pharmaceutical Industries

Source: AIOCD data base, ICICIdirect.com Research

Exhibit 6: Market share in Indian formulations market

Exhibit 7: Top 10 brands performance

8.3 8.3 8.3

8.9 8.9 9.0 8.8 8.9 8.9 8.8

Sun Pharmaceutical Industries

Aug' 16 Aug' 15 Var. (%) July' 16 Var. (%)

Source: AIOCD data base, ICICIdirect.com Research * Included Ranbaxys sales

Source: AIOCD data base, ICICIdirect.com Research

Exhibit 8: Contribution of therapies to domestic sales (MAT Aug16)

Exhibit 9: Therapy wise performance

Source: AIOCD data base, ICICIdirect.com Research

ICICI Securities Ltd. | Retail Equity Research

Source: AIOCD data base, ICICIdirect.com Research

Acute : Chronic contribution (MAT Aug16)

September 21, 2016

Source: NSE, ICICIdirect.com Research

Indian Pharma Market

Brands contribution to domestic sales (MAT Aug16)

Source: AIOCD data base

Exhibit 10: Company growth vis--vis Indian pharma market growth

Source: AIOCD data base, ICICIdirect.com Research

Exhibit 11: Market share in Indian formulations market

Exhibit 12: Top 10 brands performance

Aug' 16 Aug' 15 Var. (%) July' 16 Var. (%)